Key Takeaway: Ovid has signed an exclusive license agreement with AstraZeneca for early-stage compounds targeting the KCC2 transporter, including its lead compound, OV350. The collaboration with Tufts Laboratory, led by Dr. Stephen Moss and Dr. Jamie Maguire, aims to advance research on these compounds. This partnership is expected to enhance the development of neuropharmacological therapies.
Price reaction · baseline $3.5 (2023-09-22T15:59:00.000Z) · hit during market hours · 32 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+4%
Market Sentiment Analysis
POSITIVE FACTORS
Ovid's exclusive license agreement with AstraZeneca enhances research capabilities.
Collaboration with Tufts Laboratory is expected to advance KCC2 compound studies.
OV350 is highlighted as a lead compound with potential therapeutic benefits.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Full Press Release Details
Ovid entered into an exclusive license agreement with AstraZeneca for a portfolio of early-stage, small molecule compounds targeting the KCC2 transporter, including our lead compound, OV350. Tufts Laboratory and AstraZeneca were previously collaborating to advance studies on OV350, with Dr. Moss joined by Dr. Jamie Maguire, an expert in neuropharmacology on GABA receptor research. Ovid is continuing the collaboration with Tufts Laboratory and Dr. Moss to progress our library of KCC2 compounds.
Read press release »
Frequently Asked Questions
What is the focus of Ovid's collaboration with AstraZeneca?
The collaboration focuses on early-stage small molecule compounds targeting the KCC2 transporter.
Who is leading the research at Tufts Laboratory?
Dr. Stephen Moss is leading the research, alongside Dr. Jamie Maguire.
What is the lead compound mentioned in the article?
The lead compound mentioned is OV350.
What is the goal of the collaboration with Tufts Laboratory?
The goal is to progress the library of KCC2 compounds.
Biotech snapshot
Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk
Catalyst track record
+622%
best trade around OVID's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.